A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

• Published in: Breast cancer research and treatment Vol. 189; no. 2; pp. 455 - 461
• Main Authors: Fujii, Takeo, Masuda, Hiroko, Cheng, Yee Chung, Yang, Fei, Sahin, Aysegul A., Naoi, Yasuto, Matsunaga, Yuki, Raghavendra, Akshara, Sinha, Arup Kumar, Fernandez, Jose Rodrigo Espinosa, James, Anjali, Yamagishi, Keisuke, Matsushima, Tomoko, Schuetz, Robert, Tripathy, Debu, Tada, Sachiyo, Jackson, Rubie S., Noguchi, Shinzaburo, Nakamura, Seigo, Acoba, Jared D., Ueno, Naoto T.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2021; Springer; Springer Nature B.V
• Subjects: Adjuvant treatment; Breast cancer; Cancer; Cancer research; Care and treatment; Cytotoxic agents; Cytotoxicity; Diseases; Endocrine therapy; Epidemiology; ErbB-2 protein; Formaldehyde; Genes; Genetic aspects; Invasiveness; Medicine; Medicine & Public Health; Oncology; Paraffin; Patients; Relapse; Risk factors; RNA; Recurrence Score; Breast cancer; 21-gene signature assay; 95-gene signature assay; Estrogen receptor-positive

Purpose A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratify patients with intermediate RS into high (95GC-H)...